Turkcu, Fatih MehmetYuksel, HarunSahin, AlparslanMurat, MehmetBozkurt, YasarCaca, Ihsan2024-04-242024-04-2420130165-57011573-2630https://doi.org/10.1007/s10792-012-9646-xhttps://hdl.handle.net/11468/14674Phosphodiesterase-5 (PDE5) inhibitors are commonly used in the treatment of erectile dysfunction. There are a small number of case reports that associate this agent with central serous chorioretinopathy (CSCR). Our report presents the treatment approach to a 42-year-old patient who described blurred vision and metamorphopsia and was diagnosed with CSCR following the use of tadalafil, a PDE5 inhibitor.eninfo:eu-repo/semantics/closedAccess[No Keyword]Article332177180WOS:0003156210000132-s2.0-848794640432306501610.1007/s10792-012-9646-xQ2N/A